文献速递泌尿男性生殖肿瘤

BRCA突变携带者基于影像的前列腺癌筛查首轮结果

Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
PubMed 文献 · Ann Oncol · 2020-09-18

该研究纳入188例40-70岁BRCA1/2胚系突变男性,首轮筛查采用PSA和前列腺mpMRI,发现8.5%诊断为前列腺癌,其中44%为中高危。mpMRI筛查仅漏诊1例(6%),而年龄分层PSA会漏诊5例(31%)。决策曲线分析显示mpMRI筛查净获益最高,尤其55岁以下男性。

要点

  • BRCA携带者前列腺癌患病率8.5%,中高危占44%
  • mpMRI筛查漏诊率6%,年龄分层PSA漏诊率31%
  • 55岁以下携带者可能受益于初始MRI筛查

核心结论

  • BRCA携带者前列腺癌患病率较高,年龄可能影响筛查策略,年轻携带者可从初始MRI筛查中获益,55岁以上应使用PSA并在升高时转诊mpMRI。

研究设计与样本

  • 前瞻性首轮筛查研究,招募188例40-70岁BRCA1/2胚系突变男性(108例BRCA1,80例BRCA2),平均年龄54岁(9.8)。

主要发现

  • mpMRI筛查仅漏诊1例癌症(6%),而年龄分层PSA会漏诊5例(31%)。
  • 决策曲线分析显示,无论PSA如何,mpMRI筛查对前列腺癌诊断的净获益最高,尤其在55岁以下男性中。
  • BRCA1与BRCA2携带者前列腺癌风险无差异(8.3% vs 8.7%,P=0.91)。

关键数值与推荐

  • PSA年龄分层阈值:40-50岁≥1 ng/ml,50-60岁≥2 ng/ml,60-70岁2.5 ng/ml。
  • PSA升高和/或mpMRI可疑病灶者接受前列腺活检。

临床怎么用

  • BRCA携带者前列腺癌筛查可考虑结合mpMRI,年轻携带者(<55岁)可能从初始MRI筛查中获益。
  • 55岁以上BRCA携带者应使用PSA筛查,PSA升高时转诊mpMRI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Male-carriers of BRCA1/2 gene mutations have an increased risk of prostate cancer (PCa) with a more aggressive phenotype. Current screening-guidelines suggest the use of prostate-specific antigen (PSA) only among BRCA2 carriers. Female carriers have extensive guidelines that include imaging. Our objective was to test the prevalence of PCa among BRCA carriers and examine screening strategies, using PSA and multiparametric magnetic resonance imaging (mpMRI). PATIENTS AND METHODS: We recruited men aged 40-70 years with BRCA1/2 germline mutations and no prior history of prostate biopsy. All men underwent an initial round of screening which included PSA, and prostate mpMRI. PSA was considered elevated using an age-stratified threshold of ≥1 ng/ml for 40-50 years of age, ≥2 ng/ml for 50-60 years of age, and 2.5 ng/ml for 60-70 years of age. Men with elevated PSA and/or suspicious lesion on mpMRI were offered a prostate biopsy. PSA levels, MRI findings, PCa incidence, and tumor characteristics were evaluated. Decision curve analysis was used to compare screening strategies. RESULTS: We recruited 188 men (108 BRCA1, 80 BRCA2), mean age 54 years (9.8). One hundred and ten (57%) had either elevated age-stratified PSA (75; 40%), a suspicious MRI lesion (67; 36%), or both (32; 17%). Of these, 92 (85%) agreed to perform a prostate biopsy. Sixteen (8.5%) were diagnosed with PCa; 44% of the tumors were classified as intermediate- or high-risk disease. mpMRI-based screening missed only one of the cancers (6%), while age-stratified PSA would have missed five (31%). Decision curve analysis showed that mpMRI screening, regardless of PSA, had the highest net benefit for PCa diagnosis, especially among men younger than 55 years of age. We found no difference in the risk of PCa between BRCA1 and BRCA2 (8.3% versus 8.7%, P = 0.91). Ninety percent had a Jewish founder mutation, thus the results cannot be generalized to all ethnic groups. CONCLUSIONS: PCa is prevalent among BRCA carriers. Age may affect screening strategy for PCa in this population. Young carriers could benefit from initial MRI screening. BRCA carriers aged older than 55 years should use PSA and be referred to mpMRI if elevated. TRIAL REGISTRATION: ClinicalTrial.gov ID: NCT02053805.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Segal N, Ber Y, Benjaminov O, et al. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening. Ann Oncol. 2020. PMID: 32958357. doi:10.1016/j.annonc.2020.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。